Doximity: The Hub of Healthcare - [Business Breakdowns, EP.236]

Summary

• Doximity is best understood as three familiar businesses stacked on one audience: “to the investor, it would be like a Bloomberg or a FactSet… to the advertiser, it’s more like a Facebook.” The host notes that 80% of doctors are on the platform; Jim Jones of William Blair explains that it bundles a newsfeed, DocuSign-like signing, secure messaging, telehealth dialing, and now AI scribing and clinical reference — all free to physicians, monetized primarily by pharma advertising, because “doctors will tell you who they are. ‘I’m a radiologist in Milwaukee.’”
• The core secular thesis: healthcare digital ad penetration sits at roughly half the ~75% seen across the rest of the economy, and closed-loop ROI measurement is helping drive the shift. The market grows 5–7% a year, pharma spends ~$10B on direct-to-consumer plus ~$7B direct-to-physician, and an executive order requiring 30 seconds of risk disclosure in TV drug ads is making the DTC channel less attractive just as “no-see doctors” reduce the appeal of the rep-and-donuts model.
• The financial profile is extreme: ~90% gross margins, 55% EBITDA margins, 54% operating margins, and only 1% of revenue going to CapEx. As eyeballs grow, ad inventory grows with limited incremental expense, funding R&D reinvestment without denting margins; the balance sheet holds $900M net cash ($5/share) deployed into buybacks and acquisitions like an AI engine for clinical reference and scribing.
• Jim’s moat argument is deliberately unheroic: Doximity wins by being “good enough” across many tools in one place, not best-in-class in any. Point solutions are the constant competitive threat — and the AI risk case is a point solution that’s “wildly better” — but the one-stop platform open all day is what keeps doctor attention, and engagement “is probably the number one KPI.”
• Wallet-share gains compound on top of the secular shift: Doximity’s wallet share among $100M+ pharma brands has climbed from 10% to more than 50%, with the new “Portal” giving pharma real-time feedback on ad performance to support additional budget. Additional vectors include new biotech and pharma customers launching digital-first without an army of salespeople, CTV dollars moving in Doximity’s direction, and — “if you wanna dream the dream” — medtech and diagnostic companies.
• On valuation, Jim rejects the sell side’s price-to-sales habit: “price to sales multiples were invented for companies that had no earnings and cash flows. This business already has that.” He puts a multiple on cash flows sized to the duration of the secular shift plus share gains, and argues that ad-tech skepticism about durability may understate the opportunity — he sees “the platform that happens to monetize ad tech.”
• Key macro risk runs through pharma profitability: a discussion of tariffs, drug-price caps, or a push to put U.S. consumers on fewer drugs could reduce ad budgets “and therefore Doximity.” The thesis-level risk is a misstep in staying ahead of what doctors want, since any erosion of engagement is the first signal that competition is biting.

Deep dive

1. A workflow platform wearing a social network’s clothes

• Jim’s opening definition: Doximity is “a digital workflow platform that is purpose-built for healthcare professionals” — doctors, registered nurses, graduating students, nurse practitioners, and physician assistants. It started as “a LinkedIn for doctors” with referrals and job postings, then layered on “capabilities that are similar to DocuSign, Zoom, Slack, a newsfeed, New York Times sort of thing, and then increasingly Scribe functionality and ChatGPT.”
• The dual-analogy framing that carries the whole episode: to the doctor it’s a Bloomberg/FactSet you’re “just on all the time”; to the advertiser it’s a Facebook, because doctors identify themselves and let pharma target them with precision.
• Founder pedigree matters here: CEO Jeff previously had Epocrates, a late-1990s digital drug reference guide that eventually went public and was sold to athenahealth, before founding Doximity in 2010 with Nate Gross and Sherry Buck. Doximity went public in 2021.

2. Free tools for doctors, pharma pays the bills

• The engagement machine is unapologetically doctor-first: ML-filtered news (“cutting the scut”), CME credits earned by reading on-platform, HIPAA-compliant signing and digital fax, secure messaging, and a telehealth dialer that shows the hospital’s caller ID so patients pick up without getting the doctor’s cell number. One ad appears in every 11 news items.
• Monetization is primarily ad-based, with most revenue coming from pharma advertising to prescribing doctors; hospitals can buy enterprise Dialer Pro agreements, but doctors can use the tools for free. Jim wouldn’t be surprised by future system-level subscription revenue for AI tools — but “the last thing that they wanna do is upset doctors or give them a reason to leave the platform.”

3. The secular shift: half-penetrated digital, measurable ROI, traditional channels under pressure

• The market grows 5–7% annually on the shift from traditional channels; digital is ~75% penetrated across the economy but “about half that in healthcare.” The unlock is attribution: target a doctor cohort, buy third-party data, “see who’s getting the prescriptions” — versus a TV spot where there is no clear way to know whether the viewer saw the ad and filled a prescription.
• Matt’s probe on COVID distortion: Jim says it “pushed some pharma into the digital channel maybe a little faster,” but the durable change is generational — rising “no-see doctors” who no longer want the box-of-donuts, steak-dinner rep visit.
• Share-shift sources are stacking up: fewer pharma reps, banner ads and print as traditional sources, and DTC TV ads under pressure from an executive order requiring 30 seconds of risk disclosure — “it sounds a lot less appealing after 30 seconds of all the things that could go wrong.” With ~$10B in DTC and ~$7B in physician-directed spend, dollars are shifting both within and between buckets.
• The risk transmission is clean: a discussion of tariffs, price caps, a push to put U.S. consumers on fewer drugs, or anything else that dents pharma profitability could reduce advertising and “therefore Doximity.”

4. Extreme margins, a cash pile, and a “good enough” platform strategy

• The numbers: ~90% gross margins, 55% EBITDA, 54% operating, 1% of revenue to CapEx, with “incredibly high” incremental margins as inventory scales with eyeballs at limited incremental expense. Net cash of $900M ($5/share) funds buybacks and engagement-driving M&A, including a recently acquired AI engine for clinical reference and scribing.
• Jim’s honest framing of the AI risk: if point solutions emerge that are “wildly better, then that’s certainly a risk.” But the platform thesis is explicit modesty — Doximity “doesn’t necessarily need to be the number one telehealth provider and the number one transcriber”; being good enough in one always-open place “proves to win the day.” Product ideas come partly from an annual 36-hour meeting with its doctor board.
• The AI upside case: the scribe “makes doctors incredibly happy because they’re not spending their evenings writing reports,” and clinical reference means time-on-platform “goes up quite a bit” — which directly raises ad-inventory value.

5. Wallet share, valuation discipline, and why duration is debated

• Growth stacks beyond the secular shift: the count of $100M+ pharma brands is rising, Doximity’s wallet share among them is climbing from 10% to more than 50%, the new Portal gives brands real-time feedback on ad performance that can pull in incremental budget, and digital-first biotechs adopt earlier (“they don’t have an army of salespeople to begin with”). Medtech and diagnostic companies are a theoretical additional market, though “a little bit of an afterthought” while there is still “a lot of road to hoe” in pharma.
• Jim’s valuation stance, worth keeping verbatim: “price to sales multiples were invented for companies that had no earnings and cash flows… This business already has that.” He values cash flows against the expected duration of the shift plus share gains — and thinks ad-tech history may make investors wary of crediting that duration: it’s “the platform that happens to monetize ad tech.”
• His closing lesson: high customer value proposition plus long runway plus strong incremental margins “is a recipe for rapidly increasing earnings power… things can get pretty good pretty quickly” — conditional, as always, on holding doctor engagement.